Consider a formulation plant in Hyderabad. It produces paracetamol tablets for African markets, antibiotics for the UK, and cardiovascular capsules for Southeast Asia. That plant accounts for roughly 400 workers and millions of doses a month. Yet almost every gram of the critical chemical that makes those tablets active pharmaceutical ingredients — arrives in a sealed drum from a city in China. The plant has no backup supplier. A factory shutdown across the border, a port closure, a container shortage — and production stops within weeks.

This is not a hypothetical. India experienced exactly this vulnerability during 2020, when supply disruptions forced the government to restrict exports of 26 essential drugs including antibiotics and paracetamol, because the domestic supply of their

...

Consider a formulation plant in Hyderabad. It produces paracetamol tablets for African markets, antibiotics for the UK, and cardiovascular capsules for Southeast Asia. That plant accounts for roughly 400 workers and millions of doses a month. Yet almost every gram of the critical chemical that makes those tablets active pharmaceutical ingredients — arrives in a sealed drum from a city in China. The plant has no backup supplier. A factory shutdown across the border, a port closure, a container shortage — and production stops within weeks.

This is not a hypothetical. India experienced exactly this vulnerability during 2020, when supply disruptions forced the government to restrict exports of 26 essential drugs including antibiotics and paracetamol, because the domestic supply of their underlying bulk drug manufacturing ingredients had dried up. The lesson was stark: India leads global generic drug manufacturing by volume, but still imports an estimated 35% of its total API requirements — and for 53 critical molecules, import dependence from a single source exceeds 90%.

That structural gap is now the foundation of one of India's most compelling business ideas for a first-time MSME founder: building a domestic API or bulk drug manufacturing unit that fills an urgent, government-backed, growing, and export-ready market gap.

India API Market Size (2025)	USD 14.18 billion (Mordor Intelligence, 2026)
Projected Market Size (2031)	USD 22.18 billion | CAGR: 7.74% (2026–2031)
India's Global Rank	3rd largest API producer; 8% share of global API industry (IBEF, Nov 2024)
Min. Investment for Entry	₹2 crore–₹8 crore (semi-synthetic antibiotics); ₹15–50 crore (chemical synthesis APIs)
Key Manufacturing States	Telangana, Andhra Pradesh, Gujarat, Himachal Pradesh, Maharashtra
Key Licence Required	Manufacturing Licence under Drugs & Cosmetics Act (Schedule M, GMP-compliant plant)

The single strongest argument for entering API manufacturing in India today is structural rather than cyclical: global pharma supply chains are being redesigned, and India is the primary beneficiary. The US Biosecure Act of 2024, which restricts American pharma companies from sourcing from specific Chinese suppliers, triggered a 50% surge in request-for-quotation volumes at Indian contract manufacturers in 2024 alone, according to Mordor Intelligence (2026). Western buyers are not simply looking for backup suppliers — they are building permanent alternative supply chains. India, with its cost advantage, regulatory credentials, and depth of chemistry talent, is where those supply chains are being anchored.

Demand Drivers: Five Forces Converging

Chronic disease prevalence: Diabetes, cardiovascular conditions, and oncology cases are rising across India and globally. WHO projects that non-communicable diseases will account for over 70% of deaths worldwide by 2030. Every new formulation for these conditions requires a corresponding API. The domestic demand pipeline for cardiovascular, anti-diabetic, and oncology APIs is structurally growing with no ceiling in sight.

Generic drug expansion: India is the world's largest supplier of generic medicines by volume, covering roughly 20% of global generic market output (PHARMEXCIL). Every generic formulation requires an API, and as global patent cliffs create hundreds of new off-patent molecules each year, the demand for generic APIs grows correspondingly.

Import substitution: India's API imports from China grew by nearly 45% — from ₹18,646 crore in FY 2020–21 to ₹27,032 crore in FY 2024–25. This is a policy emergency, not just a business statistic. The government has responded with ₹6,940 crore in PLI scheme funding specifically for bulk drugs and APIs, and with dedicated Bulk Drug Park infrastructure in three states. Institutional pharma buyers — including large domestic formulators — are actively seeking domestic API suppliers to reduce their own single-source risk. For a new manufacturer, this means genuine commercial pull, not just speculative demand.

Export growth momentum: India's total pharma exports crossed USD 30.47 billion in FY 2024–25 — the first time the sector crossed the USD 30 billion milestone (PHARMEXCIL/Ministry of Commerce, 2026). APIs contributed a significant share of this total. The US, UK, and European markets actively prefer Indian-origin APIs, and over 60% of India's pharma exports already go to highly regulated markets, validating the quality credentials of the domestic industry.

Policy tailwind: The PLI scheme for bulk drugs is a time-limited, precision incentive offering 10–20% financial returns on incremental sales for six years. Eligible manufacturers of chemical synthesis APIs earn 10% per annum for six years; fermentation-based APIs earn 20% for the first four years. These are not grants — they are performance-linked income supplements that significantly improve project economics for a qualifying plant. The window for these incentives runs to FY 2028–29, making the next two to three years the ideal entry window.

Market Shift in Numbers India: Net Importer → Net Exporter India turned from a net bulk drug importer (deficit of ₹1,930 crore in FY 2021–22) to a net exporter (surplus of ₹2,280 crore in FY 2024–25). This policy-driven reversal happened in just three years — and it is still early. (PIB / Department of Pharmaceuticals, 2025)

The India API market was valued at USD 14.18 billion in 2025 and is projected to reach USD 22.18 billion by 2031 at a CAGR of 7.74% (Mordor Intelligence, 2026). Other research bodies estimate an even higher trajectory — Vantage Market Research projects the market reaching USD 37.11 billion by 2032 at a CAGR of 12.33%, while Market Research Future projects USD 236.66 billion by 2035 at a CAGR of 9.32%, reflecting different methodology and scope assumptions. A conservative working estimate of 8–9% CAGR through 2035 is supported by the convergence of multiple data sources.

End-user demand is broad and deep. Cardiovascular APIs held the largest segment share (23.20% of India API market turnover in 2025), followed by anti-infective, central nervous system, and gastroenterology APIs. The oncology segment, though smaller, is the fastest-growing, with an estimated 8.55% CAGR through 2031 (Mordor Intelligence), driven by targeted therapy launches and biosimilar development. Over 500 different APIs are manufactured in India today, but the country still relies heavily on imports for approximately 70% of fermentation-based APIs — a clearly defined gap that new manufacturers can target.

Year-Wise India API Market — Historical Data and Forecast to 2035

Year	Estimated Market Size	Key Context
FY 2020–21	~USD 9.5 billion (industry estimate)	COVID-driven API demand surge; supply chain vulnerabilities exposed
FY 2021–22	~USD 10.8 billion (industry estimate)	PLI Bulk Drugs scheme operational; domestic capacity creation begins
FY 2022–23	~USD 11.5 billion (industry estimate)	Export-linked demand rises; DMF filings with USFDA accelerate
FY 2023–24	~USD 13.0 billion (industry estimate)	De-China sourcing push; Biosecure Act signals reshape buyer behaviour
FY 2024–25	USD 14.18 billion (Mordor Intelligence)	India crosses net-exporter status for bulk drugs; RFQ volumes jump 50%
FY 2025–26 (F)	USD 15.28 billion (Mordor Intelligence)	Bulk Drug Parks in AP, Gujarat, HP begin commercial operations
FY 2028–29 (F)	~USD 18 billion (8% CAGR assumption)	PLI scheme reaches end of incentive period; established new capacity online
FY 2030–31 (F)	USD 22.18 billion (Mordor Intelligence)	Second wave of HPAPI and biosimilar API demand from global buyers
FY 2034–35 (F)	~USD 29–32 billion (8–9% CAGR assumption)	India projected to rank among top 3 global API suppliers by value

Note: Forecast figures marked (F) are projections based on stated CAGR assumptions. Historical figures for FY 2020–24 are industry estimates unless otherwise attributed. Sources: Mordor Intelligence (2026), PHARMEXCIL, Department of Pharmaceuticals.

India API Exports — Record High ₹508 crore exported under PLI alone Under the PLI Bulk Drugs scheme alone, cumulative exports of ₹508.12 crore were reported by September 2025 — from products that did not exist domestically just three years ago. Total pharma exports crossed USD 30.47 billion in FY 2024–25, a new milestone. (Department of Pharmaceuticals; PHARMEXCIL, 2025)

For a first-time entrepreneur evaluating any business, government data is the most credible signal. In the API manufacturing business, that data tells a consistent and compelling story: the state has deployed substantial capital, the policy architecture is in place, and measurable results are already visible. This is not promotional language — it is the direct output of ministry reports and parliamentary replies.

The PLI Scheme for Bulk Drugs, operated by the Department of Pharmaceuticals under the Ministry of Chemicals & Fertilizers, had an approved outlay of ₹6,940 crore. By September 2025, actual investment in greenfield plants had already reached ₹4,763.34 crore — exceeding the committed target of ₹4,329.95 crore by a meaningful margin. Of the 48 approved projects covering 33 drugs, 34 had been commissioned by late 2024. Production capacity has been created for 26 APIs, KSMs, and intermediates that were previously almost entirely imported (Department of Pharmaceuticals parliamentary reply, 2025).

The PLI Scheme for Pharmaceuticals (broader than the bulk drugs scheme) has driven even larger numbers. By December 2025, cumulative pharma PLI investments had reached ₹41,943 crore — more than double the scheme's original investment commitment of ₹17,275 crore. Cumulative sales reached ₹3,35,036 crore across 1,988 products, including exports worth ₹2,15,248 crore (Manufacturing Today India, March 2026).

The DPIIT (Department for Promotion of Industry and Internal Trade) approved 13 FDI proposals worth ₹7,246.40 crore for brownfield pharmaceutical projects in FY 2024–25 alone — a signal that large domestic and international players see long-term value in India's API manufacturing base. For MSMEs and first-time entrepreneurs, this validates the sector rather than competing directly with it: large players concentrate on complex and capital-intensive APIs, leaving significant space in mid-range molecules and contract manufacturing.

Government & Department Statistics Table: API and Bulk Drug Sector

Data Point	Figure / Status	Source & Year
PLI Bulk Drugs scheme outlay	₹6,940 crore (total)	Dept. of Pharmaceuticals, GoI
Actual investment under PLI Bulk Drugs	₹4,763.34 crore (Sept 2025)	Parliamentary reply, 2025
APIs / KSMs commissioned under PLI	26 products (Dec 2024 data); 34 projects commissioned	Dept. of Pharmaceuticals, 2025
Imports avoided via PLI Bulk Drugs	₹1,807.32 crore (cumulative to Sept 2025)	Parliamentary reply, 2025
PLI Pharmaceuticals cumulative investment	₹41,943 crore (Dec 2025)	Manufacturing Today India / DoP
DPIIT FDI approvals (pharma, FY 2024–25)	13 brownfield proposals worth ₹7,246.40 crore	DPIIT, 2025
India's API share — WHO prequalified list	57% of all WHO-prequalified APIs supplied by India	IBEF, Nov 2024
India pharma export milestone	USD 30.47 billion (FY 2024–25) — first USD 30 bn crossing	PHARMEXCIL / Ministry of Commerce, 2026
Number of APIs manufactured in India	500+ APIs; 191 manufactured in India for first time under PLI	IBEF; Dept. of Pharmaceuticals, 2025
Bulk Drug Parks approved	3 parks (Andhra Pradesh, Gujarat, Himachal Pradesh) — combined outlay ₹6,306.68 crore	Dept. of Pharmaceuticals, 2025

India's support architecture for API and bulk drug manufacturing is more structured today than at any point in the past two decades. Here is what a new entrepreneur can actually access.

PLI Scheme for Bulk Drugs (Central): Financial incentive of 10% on incremental sales (chemical synthesis) or 20% for four years declining to 5% (fermentation-based) for six production years, running from FY 2022–23 to FY 2028–29. The scheme covers 41 identified APIs and KSMs for which India has the highest import dependence. New applicants can access the scheme via the official portal (plibulkdrugs.ifciltd.com); applications for new rounds remain open periodically. Cumulative incentives available range from ₹5 crore to ₹50 crore per eligible unit depending on molecule and production scale.

Scheme for Promotion of Bulk Drug Parks: Three parks have received central approval in Andhra Pradesh (Visakhapatnam), Gujarat (Jambusar), and Himachal Pradesh (Una), each receiving ₹1,000 crore in central assistance. Setting up within one of these parks gives a new unit access to common effluent treatment, utilities, solvent recovery, and shared testing laboratories — meaningfully reducing both capex and compliance costs for a greenfield unit.

PLI Scheme for Pharmaceuticals (Broader): With an outlay of ₹15,000 crore, this scheme incentivises high-value pharmaceutical products including biopharmaceuticals and complex generics, with financial incentives to 55 selected applicants. It is particularly relevant for manufacturers looking to move up the value chain toward complex APIs, biosimilar intermediates, or innovative drug substances.

CGTMSE (Credit Guarantee Fund Trust for MSMEs): Provides collateral-free credit guarantees of up to ₹5 crore for MSME borrowers. For a first-time API entrepreneur without significant collateral, this is often the most accessible financing route for initial plant and working capital. Access is triggered by Udyam registration on the MSME portal.

SIDBI Priority Sector Lending and Technology Upgradation: SIDBI's pharmaceutical MSME lending window provides working capital financing specifically suited to API manufacturing, which requires large upfront raw material purchases before a batch can be released and sold.

RoDTEP (Remission of Duties and Taxes on Exported Products): API exporters can claim RoDTEP benefits to recover embedded taxes in the export supply chain. Combined with PHARMEXCIL's Market Access Initiative (MAI) support for overseas marketing, this makes export-oriented API units significantly more competitive on price.

DGFT Advance Authorisation Scheme: Provides customs duty exemption on imported chemical intermediates and Key Starting Materials used in producing export-bound APIs. This is especially valuable for entrepreneurs targeting regulated markets where price competitiveness depends on input cost management.

State-Level Incentives: Telangana, Andhra Pradesh, Gujarat, and Himachal Pradesh offer capital subsidy, GST reimbursement, power tariff concessions, and single-window clearance for pharma manufacturers. Telangana's Pharma City and Andhra Pradesh's state industrial development board have active schemes for API units.

India's pharmaceutical export numbers create a structural puzzle that spells opportunity. The country exports over USD 30 billion worth of medicines annually, yet a significant portion of the APIs inside those medicines still comes from abroad — primarily China. API imports from China rose from ₹18,646 crore in FY 2020–21 to ₹27,032 crore in FY 2024–25, a 45% increase in rupee terms. Meanwhile, domestic API production capacity is scaling. The gap between these two trajectories is the business opportunity.

Import substitution opportunity: For 53 critical API molecules, India's import dependence from a single source exceeds 90%. These include fermentation-based antibiotics such as Penicillin G, Amoxicillin, and Clavulanic Acid; vitamins; and several cardiovascular and anti-diabetic intermediates. New domestic capacity in these molecules attracts institutional support from both the government (via PLI incentives) and from large domestic formulators that want to derisk their sourcing.

Export market opportunity: The primary export market for Indian APIs is the United States — which accounted for approximately 31% of India's total pharma exports — followed by the UK (21% growth year-on-year in FY 2023–24), Germany, South Africa, Brazil, and the Middle East. African and Southeast Asian markets are growing fast as destinations for affordable generic APIs. Critically, over 57% of WHO-prequalified APIs come from India, giving the country an established trust advantage in regulated and semi-regulated markets.

Competitive advantage for a new Indian manufacturer: India's cost of chemistry labour is 30–40% lower than in the US or Europe. The country has a deep pool of trained chemists and chemical engineers, a well-established export logistics infrastructure, and an existing network of regulatory consultants with USFDA DMF filing experience. A new unit targeting mid-volume, mid-complexity APIs for domestic formulators or Southeast Asian buyers can be competitive without USFDA approval from Day 1 — and can build toward regulated market access as the business matures.

Company	Headquarters	Specialisation / Note
Divi's Laboratories Ltd.	Hyderabad, Telangana	Custom synthesis and generic API specialist; exports to 95+ countries; preferred CDMO partner for global MNCs
Dr. Reddy's Laboratories	Hyderabad, Telangana	Vertically integrated; strong in oncology, cardiovascular, CNS; USFDA, EMA, PMDA approved
Sun Pharmaceutical Industries	Mumbai, Maharashtra	India's largest pharma company; broad API portfolio including peptides, steroids, and cardiovascular molecules
Aurobindo Pharma Ltd.	Hyderabad, Telangana	Among top API exporters; 11 dedicated API units; exports to 150+ countries with USFDA, MHRA approvals
Cipla Ltd.	Mumbai, Maharashtra	Legacy API player; strong in respiratory, oncology, and affordable global health APIs
Lupin Ltd.	Mumbai, Maharashtra	Strong USFDA-approved API capacities; growing CDMO business targeting Western pharma companies
Laurus Labs Ltd.	Hyderabad, Telangana	Fast-growing CDMO and API player; notable oncology injectables facility opened 2024; MSME-to-large-scale growth story
Macsen Labs (MSME scale)	Udaipur, Rajasthan	USFDA-inspected MSME API manufacturer; WHO-GMP and TGA-GMP certified; actively expanding capacity under PLI framework

From the Consultant's Chair: Don't Start General — Start Specific The most common mistake I see in first-time API business plans is the decision to manufacture a commodity antibiotic where 40 other small units already compete. Pick a molecule with genuine scarcity — ideally one of the 41 PLI-notified APIs for which India still imports heavily — or a therapeutic niche (oncology intermediates, cardiovascular APIs for the domestic market) where buyers will pay for reliability and compliance over the lowest price. The PLI scheme was built precisely to reward this kind of targeted entry. A unit focused on one or two well-chosen APIs with a clear buyer pipeline will outperform a generalised facility every time.

Working from a 2025 base of approximately USD 14.18 billion and applying an 8–9% annual CAGR — supported by multiple independent research bodies and grounded in the structural demand drivers described above — India's API market can reasonably be expected to reach USD 28–32 billion by FY 2034–35. That projection assumes continued global generic drug demand growth, sustained progress on import substitution under PLI, and progressive capacity ramp-up at Bulk Drug Park facilities in Andhra Pradesh, Gujarat, and Himachal Pradesh.

The high-potency API (HPAPI) segment is particularly important for the medium-term horizon. Low- and medium-strength APIs currently account for 85.90% of India's API market by value, but HPAPIs — used primarily in oncology and targeted therapies — are forecast to grow at 8.79% CAGR through 2031 (Mordor Intelligence), driven by the global pipeline of targeted cancer treatments. India's oncology drug manufacturers are already building domestic API sourcing relationships for these molecules, and the investment required is higher but so are the margins.

For a biosimilar API business, the outlook extends even further. India's biosimilar market is projected to grow at 22% CAGR (IBEF), and the API-equivalent intermediates and biological starting materials for biosimilars represent the next frontier of domestic API manufacturing. Biocon, Dr. Reddy's, and Zydus are active in this space, and the secondary and tertiary supply chain for biological APIs is still underdeveloped.

What does this mean for a business started in 2025 or 2026? It means entering during the demand acceleration phase rather than after the market has matured. The Bulk Drug Parks are still ramping up. The PLI incentive window runs to 2028–29. The Biosecure Act-driven sourcing reorientation by US and European buyers is in its early stages. A unit commissioned in FY 2026–27 has four to five PLI incentive years remaining and enters a market where institutional demand is rising, not yet saturated.

Q: How much does it realistically cost to start an API manufacturing unit in India?

Entry-level investment for a semi-synthetic antibiotic API unit (Amoxicillin, Ciprofloxacin) ranges from ₹2 crore to ₹8 crore depending on molecule and capacity. Chemical synthesis APIs — cardiovascular or anti-diabetic molecules — typically require ₹15–50 crore for a viable commercial plant. Fermentation-based APIs (Penicillin G, Clavulanic Acid) require ₹50 crore and above due to bioreactor requirements. Setting up inside a Bulk Drug Park in Gujarat, Andhra Pradesh, or Himachal Pradesh can reduce both capex and operating costs meaningfully by sharing effluent treatment, utilities, and testing infrastructure.

Q: Which APIs should a first-time manufacturer target?

Focus on molecules where India has established import dependency, manageable chemistry barriers, and existing domestic buyer demand. The 41 PLI-notified bulk drugs list is the most useful starting reference — these are precisely the molecules where government incentives are active and domestic buyers want alternatives to China-sourced material. Within that list, antibiotics (Amoxicillin, Azithromycin), cardiovascular APIs, and vitamin intermediates represent manageable chemistry complexity for a new entrant. Oncology and HPAPI segments offer higher margins but require specialised facility design and higher initial investment.

Q: Can an MSME without USFDA approval find buyers for its API?

Yes — the domestic formulation market is the natural first market. Large domestic formulators including Cipla, Sun Pharma, and Lupin are actively building dual-source API supplier relationships to reduce their China dependence. WHO-GMP certification is the minimum quality bar for most domestic and regulated-market buyers. WHO-GMP approval enables sales to African, Southeast Asian, and Middle Eastern markets, which together represent a large and growing demand pool for generic APIs. USFDA or EMA approvals unlock US and European market access but are a second-phase goal, typically two to four years into operations.

Q: What government registration does an API plant need before it can operate?

API manufacturing requires a Drug Manufacturing Licence under the Drugs and Cosmetics Act, 1940, from the State Drug Control Authority. Plants must comply with Schedule M of the Rules, which governs Good Manufacturing Practice (GMP) standards. Because API units are classified as red-category industries under environmental regulations, Environmental Clearance, Consent to Establish, and Consent to Operate from the State Pollution Control Board are mandatory before production begins. Units within Bulk Drug Parks benefit from pre-cleared environmental infrastructure, which simplifies this process significantly.

Q: Is the PLI scheme for bulk drugs still open for new applicants?

The scheme tenure runs to FY 2029–30, and the Department of Pharmaceuticals has periodically reopened applications for new rounds. As of late 2025, the scheme continues to process applications via the plibulkdrugs.ifciltd.com portal, with detailed eligibility guidelines available at pharma-dept.gov.in/schemes. Applicants who previously received approval but withdrew are no longer eligible. New entrants targeting the 41 notified molecules under chemical synthesis or fermentation routes should verify the latest open application period directly with the Department of Pharmaceuticals.

Q: How do I assess whether my chosen molecule has a realistic domestic buyer?

The most direct method is to map India's formulation export data (available via PHARMEXCIL) against the API import data (available via DGCI&S trade statistics) for your molecule. A molecule where India imports large quantities of the API but exports large quantities of the finished formulation is structurally attractive for domestic API manufacturing. Industry associations such as the Indian Drug Manufacturers' Association (IDMA) and FICCI's Pharma Committee can facilitate introductions to potential buyer formulators at an early stage.

Q: Is the contract manufacturing (CMO/CDMO) model a good entry route for a new API startup?

Yes, and for many first-time founders it is a smarter route than proprietary manufacturing. Under a contract manufacturing model, a larger formulator provides the molecule specifications and purchase commitment; you provide the plant, chemistry capability, and GMP compliance. This removes demand uncertainty from the business equation. India's CDMO sector has been growing rapidly — companies such as Laurus Labs began as small API contract manufacturers and scaled significantly. The tradeoff is lower margin compared to proprietary sales, but the trade-off is offset by revenue predictability and the operational learning that comes from working to a regulated buyer's quality standards from Day 1.

Q: What quality certifications should an API startup target first, and in what sequence?

The practical sequence is: Schedule M (GMP) compliance under the Drugs & Cosmetics Act — mandatory before any Indian sales; WHO-GMP certification — unlocks export markets across Africa, Southeast Asia, and Middle East; then ISO 9001 for quality management systems, which many domestic buyers now require alongside GMP. USFDA Drug Master File (DMF) filing is the third stage — it does not guarantee approval but is the prerequisite for any US-bound API supply. EMA CEP (Certificate of Suitability) is the European equivalent. A new startup typically reaches WHO-GMP within 18–24 months of commissioning; USFDA DMF filing is realistically a three-to-five year milestone for most MSME-scale plants.

Q: How does a new API manufacturer manage the working capital challenge?

Working capital is the primary operational challenge in API manufacturing because raw material purchases (Key Starting Materials, solvents, intermediates) are made weeks before a batch is released and sold. Three tools address this: SIDBI's pharmaceutical MSME lending provides priority-sector working capital specifically for this cycle. CGTMSE collateral-free credit of up to ₹5 crore is accessible after Udyam registration. For export-oriented units, the DGFT Advance Authorisation Scheme allows duty-free import of intermediates, which directly reduces the working capital tied up in input costs. Many successful MSME API manufacturers also negotiate advance payments from buyers — especially domestic formulators who want to secure supply commitments.

Q: How is the Biosecure Act in the US actually creating business for Indian API manufacturers?

The US Biosecure Act, passed in 2024, restricts American pharmaceutical companies from contracting with certain Chinese biotechnology suppliers. While the Act primarily targets contract research and biologics, its broader effect has been to accelerate a strategic sourcing review across all API categories by US pharma buyers who want to reduce China exposure. Mordor Intelligence reported a 50% jump in request-for-quotation (RFQ) volumes at leading Indian contract manufacturers during 2024. For an Indian API entrepreneur, the practical implication is that US-based formulators are more willing now than at any previous point to qualify a new Indian supplier — even at somewhat higher per-unit cost — in order to build supply chain resilience. This is a structural shift, not a temporary trend.

Q: What are the most common mistakes first-time API entrepreneurs make that experienced manufacturers say they wish they had avoided?

Three mistakes come up consistently in founder conversations. First: choosing a commodity molecule without a locked-in buyer before construction begins. Demand should be pre-committed before a brick is laid. Second: underestimating the time and cost of environmental clearances and effluent treatment — regulatory approvals typically take 12–18 months for a red-category industry, and this timeline is often missing from feasibility projections. Third: deferring GMP systems to a later phase. Quality systems retrofitted after production starts are vastly more expensive to implement and create batch failures. The most successful MSME API units in India — including several Macsen Labs-scale businesses — built GMP-compliant plants from Day 1 and won export contracts within their first two years of operations as a direct result.

The API manufacturing business in India has rarely been better positioned for a new entrant. The market is growing at 7–9% annually, the government is spending ₹6,940 crore specifically to incentivise domestic production, and global buyers are permanently restructuring their supply chains in favour of Indian manufacturers. The import substitution gap in 53 critical molecules is not a theoretical opportunity — it is a documented, government-acknowledged structural deficit with active financial incentives attached.

The most important support available is the PLI Bulk Drugs scheme, which adds 10–20% to your incremental sales revenue for six production years and runs to FY 2028–29. Combined with CGTMSE collateral-free credit, SIDBI working capital, and the infrastructure advantages of Bulk Drug Parks in Andhra Pradesh, Gujarat, and Himachal Pradesh, the support ecosystem for a new API unit is more complete today than it has ever been.

The demand trajectory to 2035 is clear: a market growing from USD 14 billion to an estimated USD 28–32 billion, with high-potency oncology APIs and biosimilar intermediates as the fastest-growing segments. A business started in 2025 or 2026 enters at the inflection point — while the policy window is still open and before the market reaches maturity.

The first step for any serious founder is molecule selection. Choose your target API from the PLI-notified list, confirm domestic buyer demand through PHARMEXCIL data and direct industry contact, complete a techno-economic feasibility study, and approach the Department of Pharmaceuticals for PLI eligibility guidance. The opportunity is specific, the support is real, and the window is open now.

• Mordor Intelligence (2026) — India Active Pharmaceutical Ingredients Market: size, CAGR, segment forecasts, and competitive landscape (2025–2031).

• Department of Pharmaceuticals, Ministry of Chemicals & Fertilizers, Government of India (2025) — PLI Scheme for Bulk Drugs: investment, commissioned projects, import substitution, and cumulative sales data; parliamentary reply data.

• PHARMEXCIL (Pharmaceutical Export Promotion Council of India) & Ministry of Commerce (2026) — India pharma export milestone of USD 30.47 billion in FY 2024–25; market share and export-destination data.

• IBEF (India Brand Equity Foundation) (November 2024) — India's pharmaceutical industry overview: API production rank, WHO-prequalified API share, market size projections, and sector FDI data.

• PIB (Press Information Bureau) & India Briefing (2025) — PLI scheme overall investment data (₹1.61 lakh crore committed); transition from net importer to net exporter of bulk drugs; ₹41,943 crore pharma PLI investment as of December 2025.

• Policy Circle / BioSpectrum India / FICCI (2025–2026) — Analysis of India's API import dependence, Bulk Drug Park progress, critical molecule gap analysis, and NIPER Centres of Excellence data.